Live Web Chat: Answering Questions on New Lymphoma Treatments

0

Ann LaCasce, MD, a medical oncologist in the Dana-Farber/Brigham and Women’s Cancer Center Adult Lymphoma Program, answered a variety of questions about Hodgkin and non-Hodgkin lymphoma during a live web chat hosted by Dana-Farber last month.

The chat, which featured questions submitted by patients and live viewers, focused on new treatments for lymphoma. Some of the topics discussed included new drugs Ibrutinib and Brentuximab, use of umbilical cord stem cells, and treatments with genetically engineered T-cells.

“There are some questions we still have, but I think the work around T-cells is a very exciting area in lymphoma, and it’s going to have applications in other cancers as well,” LaCasce said.

View a video of the Dec. 18 web chat below. For more information on lymphoma, visit the Dana-Farber Adult Lymphoma Program website.

Comments Sort By Newest

Leave a Reply

Your email address will not be published. Required fields are marked *

Blue Captcha Image
Refresh

*

Latest Tweets

Dana-Farber @danafarber
Shared Data: Breaking Down Silos to Conquer Cancer - https://t.co/gFPoT5a7kr #CanServe #CancerMoonshot https://t.co/Ngxncv6mjz
Dana-Farber @danafarber
How to Talk to Your Family about Genetic Cancer Risk - https://t.co/CuXqkzqaXu #cancergenetics https://t.co/o28BGjPLdy
Dana-Farber @danafarber
PROFILE #CanServe by collecting as much information and genomic data as possible for every type of cancer. https://t.co/AgYcGStBH3

Make An Appointment

For adults: 877-442-3324

Quick access: Appointments as soon as the next day for new adult patients

For children: 888-733-4662

Republish our posts on your blog

Interested in sharing one of our stories on your blog? Feel free to republish this content! We just ask that you credit Dana-Farber, link to the original article, and refrain from making edits that change the original context. Questions? Email the editors at insight_blog@dfci.harvard.edu.

All content in these blogs is provided by independent writers and does not represent the opinions or advice of Dana-Farber Cancer Institute or its partners.